Compare Sana Biotechnology Inc (SANA) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Atlassian Corporation PLC — how do they compare? Sana Biotechnology Inc trades at $2.85 (market cap $836.71M), while Atlassian Corporation PLC trades at $206.21 (market cap $51.53B). The key difference: Atlassian Corporation PLC is far larger — about 61.6× Sana Biotechnology Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Atlassian Corporation PLC for 64 Days on average.
| SANA | TEAM | |
|---|---|---|
Market Cap | $836.71M | $51.53B |
Volume | 4,507,444 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $5.92 | $203.57 |
52-Week Low | $2.68 | $57.15 |
Typical Hold Time | 23 Days | 64 Days |
Enterprise Value | $749.96M | $51.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Atlassian (TEAM) trades at $205.09, up 4.81% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with moving averages supporting upward momentum, though RSI suggests potential overbought conditions. Revenue growth remains robust at $5.22B for 2025, with improving margins despite negative net income. Recent news highlights accelerating cloud migration and AI adoption driving investor optimism.
Outlook remains positive with 69.77% analyst buy ratings and a $140B addressable market growing at 14% annually. Key risks include persistent negative profitability, high valuation multiples, and competitive pressures. The stock trades above consensus price target of $191.16, suggesting near-term consolidation potential despite long-term growth catalysts from AI and cloud expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
